 |
|
||
|
 |
||||||||||
 |
||||||||||
 |
||||||||||
|
||||||||||
 |
||||||||||
|
||||||||||
 |
||||||||||
|
||||||||||
|
 iPad compatible version can be now be downloaded |
 |
 |
| SCImago Journal & Country Rank |
 |
 |
| The African Journal Archive is a retrospective digitisation project of full-text journal articles published in Africa. Older CVJA articles can be viewed here. |
|
MEDIA RESOURCES SHIFTING the burden of heart failure Ivabradine, the pure heart rate-lowering drug, shown to reduce morbidity and mortality in heart failure. The results of the SHIfT study, announced this week at the European Society of Cardiology (ESC) 2010 congress in Stockholm, are likely to change the clinical treatment of chronic heart failure as they provide the first positive results for many years in this difficult field of treatment. The great interest in the outcome of this study was evident from the large number of delegates attending this hot-line session on the first day of the congress. Download this e-Publication report in PDF |
||
|
Innovative approaches offer more at 2010 South African Heart Association congress, 8 - 11 August, Sun City The organisers of the 2010 South African Heart Association congress (SAHA) are offering an innovative programme with sessions in cardio-oncology (a first for South Africa), women’s cardiovascular health, ethics, and South African scientific contributions within the plenary sessions. Parallel sessions, although necessary to cope with special-interest groups, will be kept to a minimum. Interventional cardiology will be well covered. Download this e-Publication report in PDF The ultimate anticoagulants? Two new anticoagulants that can be administered orally are poised to change the face of anticoagulation as we know it. Rivaroxaban and dabigatran (neither available in South Africa as yet) have both shown positive results in clinical trials. At the congress of the South African Society of Thrombosis and Haemostasis, held in Johannesburg on 22 November 2009, Profs Sylvia Haas and Ajay Kakkar presented the evidence for rivaroxaban and dabigatran, respectively.
Wherever you see this icon  ,
that journal is then available to be viewed via our online eJournal functionality. It can be accessed by clicking on the
logo or journal name. A new window will open with the selected
journal. Please note that we are currently testing our Online
eJournal
functionality.
Other Advance Publications
|
© 2011 All Rights Reserved
Disclaimer